

Robert S Brown Jr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11339147/publications.pdf>

Version: 2024-02-01

198
papers

17,719
citations

16451

64
h-index

13379

130
g-index

211
all docs

211
docs citations

211
times ranked

15931
citing authors

#	ARTICLE	IF	CITATIONS
1	Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. <i>Hepatology</i> , 2018, 67, 1560-1599.	7.3	2,620
2	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. <i>Gastroenterology</i> , 2015, 149, 649-659.	1.3	725
3	Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. <i>New England Journal of Medicine</i> , 2015, 373, 2618-2628.	27.0	692
4	COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. <i>American Journal of Transplantation</i> , 2020, 20, 1800-1808.	4.7	683
5	Prospective, Randomized, Multicenter, Controlled Trial of a Bioartificial Liver in Treating Acute Liver Failure. <i>Annals of Surgery</i> , 2004, 239, 660-670.	4.2	574
6	Recommendations for the Outpatient Surveillance of Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, S1-S86.	6.1	514
7	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. <i>Nature</i> , 2019, 575, 505-511.	27.8	493
8	Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 2992-2998.	1.6	478
9	A Survey of Liver Transplantation from Living Adult Donors in the United States. <i>New England Journal of Medicine</i> , 2003, 348, 818-825.	27.0	475
10	Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1. <i>Gastroenterology</i> , 2006, 131, 470-477.	1.3	453
11	Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. <i>Hepatology</i> , 2016, 63, 284-306.	7.3	414
12	Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. <i>Hepatology</i> , 2007, 46, 1853-1862.	7.3	367
13	Negative Impact of Neutrophil-Lymphocyte Ratio on Outcome After Liver Transplantation for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2009, 250, 141-151.	4.2	351
14	Hepatitis C and liver transplantation. <i>Nature</i> , 2005, 436, 973-978.	27.8	319
15	Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation. <i>Gastroenterology</i> , 2015, 148, 108-117.	1.3	317
16	Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial. <i>Hepatology</i> , 2007, 46, 971-981.	7.3	289
17	Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. <i>Hepatology</i> , 2016, 63, 319-333.	7.3	275
18	Clinical risk factors for portopulmonary hypertension. <i>Hepatology</i> , 2008, 48, 196-203.	7.3	239

#	ARTICLE	IF	CITATIONS
19	Improvement in Survival Associated With Adult-to-Adult Living Donor Liver Transplantation. <i>Gastroenterology</i> , 2007, 133, 1806-1813.	1.3	216
20	Genetic Risk Factors for Portopulmonary Hypertension in Patients with Advanced Liver Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 835-842.	5.6	206
21	Recurrence After Liver Transplantation for Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2017, 265, 557-564.	4.2	204
22	Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. <i>Liver Transplantation</i> , 2002, 8, 278-284.	2.4	189
23	Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study. <i>Hepatology</i> , 2011, 54, 91-100.	7.3	188
24	Live Donors in Liver Transplantation. <i>Gastroenterology</i> , 2008, 134, 1802-1813.	1.3	172
25	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2016, 150, 419-429.	1.3	166
26	Interferon Monotherapy for Dialysis Patients With Chronic Hepatitis C: An Analysis of The Literature on Efficacy and Safety. <i>American Journal of Gastroenterology</i> , 2003, 98, 1610-1615.	0.4	161
27	Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. <i>Hepatology</i> , 2018, 68, 1298-1307.	7.3	158
28	Steroid use in acute liver failure. <i>Hepatology</i> , 2014, 59, 612-621.	7.3	153
29	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020, 71, 522-538.	7.3	151
30	Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-ARGET study. <i>Hepatology</i> , 2017, 66, 1090-1101.	7.3	149
31	OUTCOME OF PATIENTS WITH RENAL INSUFFICIENCY UNDERGOING LIVER OR LIVER-KIDNEY TRANSPLANTATION ^{1,2} . <i>Transplantation</i> , 1996, 62, 1788-1793.	1.0	146
32	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018, 69, 396-405.	3.7	144
33	Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. <i>Hepatology</i> , 2014, 59, 1073-1083.	7.3	138
34	Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. <i>Hepatology</i> , 2011, 54, 1313-1321.	7.3	136
35	A Randomized Trial of Pegylated Interferon alpha-2b Plus Ribavirin in the Retreatment of Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2005, 100, 2453-2462.	0.4	127
36	Scope of worldwide hepatitis C problem. <i>Liver Transplantation</i> , 2003, 9, S10-S13.	2.4	124

#	ARTICLE	IF	CITATIONS
37	Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. <i>Liver Transplantation</i> , 2007, 13, 122-129.	2.4	119
38	Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. <i>Liver Transplantation</i> , 2003, 9, 1028-1035.	2.4	116
39	A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. <i>Hepatology</i> , 2013, 57, 1752-1762.	7.3	113
40	Standing the test of time: Outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. <i>Hepatology</i> , 2014, 60, 1957-1962.	7.3	110
41	Glecaprevir/pibrentasvir for 8-weeks in treatment-naïve patients with chronic HCV genotypes 1 and compensated cirrhosis: The EXPEDITION-8 trial. <i>Journal of Hepatology</i> , 2020, 72, 441-449.	3.7	109
42	Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. <i>Liver Transplantation</i> , 2016, 22, 24-33.	2.4	100
43	Hepatitis C Virus and Liver Transplantation. <i>Clinics in Liver Disease</i> , 2006, 10, 919-940.	2.1	93
44	Sorafenib: Where do we go from here?. <i>Hepatology</i> , 2010, 52, 360-369.	7.3	92
45	Strategies for Managing Anemia in Hepatitis C Patients Undergoing Antiviral Therapy. <i>American Journal of Gastroenterology</i> , 2007, 102, 880-889.	0.4	89
46	The Survival Impact of Liver Transplantation in the MELD Era, and the Future for Organ Allocation and Distribution. <i>American Journal of Transplantation</i> , 2005, 5, 203-204.	4.7	88
47	Is it Time to Abandon the Milan Criteria?. <i>Annals of Surgery</i> , 2018, 268, 690-699.	4.2	87
48	Long-term quality of life after liver donation in the adult to adult living donor liver transplantation cohort study (A2ALL). <i>Journal of Hepatology</i> , 2015, 62, 346-353.	3.7	85
49	Racial Disparities in Utilization of Liver Transplantation for Hepatocellular Carcinoma in the United States, 1998-2002. <i>American Journal of Gastroenterology</i> , 2008, 103, 120-127.	0.4	84
50	Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. <i>Hepatology</i> , 2011, 54, 418-424.	7.3	83
51	Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding. <i>Hepatology</i> , 2000, 31, 358-363.	7.3	77
52	A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. <i>Journal of Hepatology</i> , 2014, 61, 508-514.	3.7	75
53	Performance of the Hepatic Encephalopathy Scoring Algorithm in a Clinical Trial of Patients With Cirrhosis and Severe Hepatic Encephalopathy. <i>American Journal of Gastroenterology</i> , 2009, 104, 1392-1400.	0.4	74
54	Intestinal Virome in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020, 72, 2182-2196.	7.3	74

#	ARTICLE	IF	CITATIONS
55	Review: Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. <i>Therapeutic Advances in Gastroenterology</i> , 2010, 3, 55-66.	3.2	73
56	Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. <i>Liver Transplantation</i> , 2016, 22, 446-458.	2.4	73
57	Prevention of Post-transplant Cardiovascular Disease - Report and Recommendations of an Ad Hoc Group1. <i>American Journal of Transplantation</i> , 2002, 2, 491-500.	4.7	71
58	Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: Findings from the Antiretroviral Pregnancy Registry. <i>Journal of Hepatology</i> , 2012, 57, 953-959.	3.7	71
59	Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype 1. <i>Hepatology</i> , 2007, 46, 982-990.	7.3	70
60	Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. <i>American Journal of Gastroenterology</i> , 2003, 98, 2521-2527.	0.4	69
61	Adult Living Donor Liver Transplantation. <i>American Journal of Transplantation</i> , 2004, 4, 458-465.	4.7	69
62	Cholestatic hepatitis C following liver transplantation: An outcome-based histological definition, clinical predictors, and prognosis. <i>Liver Transplantation</i> , 2013, 19, 78-88.	2.4	68
63	Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , 2020, 40, 1841-1852.	3.9	66
64	Analysis of Failure in Living Donor Liver Transplantation: Differential Outcomes in Children and Adults. <i>World Journal of Surgery</i> , 2003, 27, 356-364.	1.6	65
65	Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 2083-2088.	4.7	64
66	Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 122-132.	8.1	63
67	Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis. <i>Hepatology</i> , 2016, 63, 307-318.	7.3	62
68	Predictors of the cost of liver transplantation. <i>Liver Transplantation</i> , 1998, 4, 170-176.	1.8	58
69	Impact of Adult Living Donor Liver Transplantation on Waiting Time Survival in Candidates Listed for Liver Transplantation. <i>American Journal of Transplantation</i> , 2004, 4, 427-431.	4.7	58
70	Liver and intestine transplantation. <i>American Journal of Transplantation</i> , 2004, 4, 81-92.	4.7	56
71	Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: A multicenter cohort study. <i>Liver Transplantation</i> , 2012, 18, 532-538.	2.4	55
72	Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2678-2687.	6.1	55

#	ARTICLE	IF	CITATIONS
73	Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants. <i>American Journal of Transplantation</i> , 2022, 22, 1925-1926.	4.7	54
74	Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. <i>Liver Transplantation</i> , 2011, 17, 409-417.	2.4	53
75	Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial. <i>Gastroenterology</i> , 2013, 145, 1035-1044.e5.	1.3	51
76	The Impact of Surgical Complications After Liver Transplantation on Resource Utilization. <i>Archives of Surgery</i> , 1997, 132, 1098.	2.2	50
77	Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 903-906.e1.	4.4	47
78	Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States. <i>Hepatology</i> , 2021, 74, 1523-1532.	7.3	47
79	SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant. <i>World Journal of Gastroenterology</i> , 2020, 26, 1546-1553.	3.3	46
80	A Review of the Current State of Liver Transplantation Disparities. <i>Liver Transplantation</i> , 2021, 27, 434-443.	2.4	44
81	Predictors of mortality and stenosis after transjugular intrahepatic portosystemic shunt. <i>Liver Transplantation</i> , 2002, 8, 271-277.	2.4	39
82	Hepatitis C and Liver Transplantation: Enhancing Outcomes and Should Patients Be Retransplanted. <i>Clinics in Liver Disease</i> , 2008, 12, 637-659.	2.1	38
83	Serotonin Transporter Polymorphisms in Patients With Portopulmonary Hypertension. <i>Chest</i> , 2009, 135, 1470-1475.	0.8	38
84	COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era. <i>American Journal of Transplantation</i> , 2022, 22, 2682-2688.	4.7	35
85	Dynamic Î±-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. <i>JAMA Surgery</i> , 2021, 156, 559.	4.3	34
86	Kidney and Liver Living Donors: A Comparison of Experiences. <i>Progress in Transplantation</i> , 2005, 15, 185-191.	0.7	33
87	Development and external validation of a prediction risk model for short-term mortality among hospitalized U.S. COVID-19 patients: A proposal for the COVID-AID risk tool. <i>PLoS ONE</i> , 2020, 15, e0239536.	2.5	33
88	Risk factors and impact of chronic obstructive pulmonary disease in candidates for liver transplantation. <i>Liver Transplantation</i> , 2008, 14, 1357-1365.	2.4	32
89	Basiliximab Induction and Delayed Calcineurin Inhibitor Initiation in Liver Transplant Recipients With Renal Insufficiency. <i>Transplantation</i> , 2011, 91, 1254-1260.	1.0	30
90	Clinical and ethnic differences in candidates listed for liver transplantation with and without potential living donors. <i>Liver Transplantation</i> , 2003, 9, 254-259.	2.4	29

#	ARTICLE	IF	CITATIONS
91	Payer status, but not race, affects the cost of liver transplantation. <i>Liver Transplantation</i> , 1998, 4, 370-377.	1.8	26
92	The North American Consortium for the Study of End-stage Liver Disease's "Acute-on-Chronic Liver Failure Score Accurately Predicts Survival: An External Validation Using a National Cohort. <i>Liver Transplantation</i> , 2020, 26, 187-195.	2.4	25
93	The Current Management of Hepatorenal Syndrome "Acute Kidney Injury in the United States and the Potential of Terlipressin. <i>Liver Transplantation</i> , 2021, 27, 1191-1202.	2.4	23
94	Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 459-68.	1.4	22
95	Financial impact of adult living donation. <i>Liver Transplantation</i> , 2003, 9, S12-S15.	2.4	21
96	The Hepatitis Aggressiveness Score (HAS). <i>American Journal of Surgical Pathology</i> , 2013, 37, 104-113.	3.7	20
97	Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH). <i>Liver International</i> , 2022, 42, 1109-1120.	3.9	20
98	Hepatitis C disease severity in living versus deceased donor liver transplant recipients: An extended observation study. <i>Hepatology</i> , 2014, 59, 1311-1319.	7.3	19
99	Hepatitis C Genotype Influences Post-liver Transplant Outcomes. <i>Transplantation</i> , 2015, 99, 835-840.	1.0	19
100	Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease. <i>Transplantation</i> , 2015, 99, 1644-1651.	1.0	19
101	Impact of Hispanic or Asian Ethnicity on the Treatment Outcomes of Chronic Hepatitis C. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 720-726.	2.2	18
102	Opioid epidemic and liver disease. <i>JHEP Reports</i> , 2019, 1, 240-255.	4.9	18
103	Hepatology Highlights. <i>Hepatology</i> , 2019, 69, 1-4.	7.3	18
104	High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy. <i>Liver International</i> , 2015, 35, 510-517.	3.9	16
105	Delayed calcineurin inhibitor introduction and renal outcomes in liver transplant recipients receiving basiliximab induction. <i>Clinical Transplantation</i> , 2018, 32, e13415.	1.6	16
106	Ethical issues in living donor liver transplantation. <i>Current Gastroenterology Reports</i> , 2003, 5, 26-30.	2.5	15
107	Predictors of Candidate Maturation Among Potential Living Donors. <i>American Journal of Transplantation</i> , 2005, 5, 2549-2554.	4.7	15
108	Role of the Independent Donor Advocacy Team in Ethical Decision Making. <i>Progress in Transplantation</i> , 2005, 15, 298-302.	0.7	14

#	ARTICLE	IF	CITATIONS
109	Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. <i>Transplant International</i> , 2017, 30, 196-208.	1.6	14
110	SARS-CoV-2 infection increases tacrolimus concentrations in solid-organ transplant recipients. <i>Clinical Transplantation</i> , 2021, 35, e14193.	1.6	14
111	Predictors of donor follow-up after living donor liver transplantation. <i>Liver Transplantation</i> , 2014, 20, 967-976.	2.4	13
112	A Call to Standardize Definitions, Data Collection, and Outcome Assessment to Improve Care in Alcohol-Related Liver Disease. <i>Hepatology</i> , 2019, 70, 1038-1044.	7.3	13
113	National Trends in Location of Death in Patients With End-Stage Liver Disease. <i>Liver Transplantation</i> , 2021, 27, 165-176.	2.4	13
114	American Gastroenterological Association Institute Technical Review on Initial Testing and Management of Acute Liver Disease. <i>Gastroenterology</i> , 2017, 152, 648-664.e5.	1.3	12
115	Liver atrophy and regeneration in noncirrhotic portal vein thrombosis: Effect of surgical shunts. <i>Liver Transplantation</i> , 2018, 24, 881-887.	2.4	11
116	Utilization of Hepatitis C Virus (HCV)-Viremic Organs for HCV Negative Recipients: Is Practice Speeding Past the Evidence?. <i>Hepatology</i> , 2020, 71, 4-7.	7.3	11
117	Management of Hepatic Coagulopathy in Bleeding and Nonbleeding Patients: An Evidence-Based Review. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 524-541.	2.8	11
118	Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials. <i>Liver International</i> , 2018, 38, 1010-1021.	3.9	10
119	Can Living Donor Liver Transplantation in the United States Reach Its Potential?. <i>Liver Transplantation</i> , 2021, 27, 1644-1652.	2.4	10
120	Is the Cost of Adult Living Donor Liver Transplantation Higher Than Deceased Donor Liver Transplantation?. <i>Liver Transplantation</i> , 2004, 10, 467-468.	2.4	9
121	Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity. <i>Clinical Transplantation</i> , 2013, 27, 829-837.	1.6	9
122	Early Postoperative Neutrophil Gelatinase-Associated Lipocalin Predicts the Development of Chronic Kidney Disease After Liver Transplantation. <i>Transplantation</i> , 2018, 102, 809-815.	1.0	9
123	Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis. <i>Hepatology Communications</i> , 2019, 3, 1388-1399.	4.3	9
124	Identifying Risk of Alcohol Relapse After Liver Transplantation: What Tools Do We Need?. <i>Liver Transplantation</i> , 2019, 25, 1133-1135.	2.4	9
125	Live donor liver transplantation: Current status. <i>Current Gastroenterology Reports</i> , 2008, 10, 36-42.	2.5	8
126	Plasma levels of S100A4 in portopulmonary hypertension. <i>Biomarkers</i> , 2009, 14, 156-160.	1.9	8

#	ARTICLE	IF	CITATIONS
127	Postpartum Laboratory Follow-up in Women With Hepatitis B in Massachusetts From 2007 to 2012. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, e60-e64.	2.2	8
128	Nonviral or Drug-Induced Etiologies of Acute Liver Failure. <i>Clinics in Liver Disease</i> , 2018, 22, 347-360.	2.1	8
129	Mortality, sepsis, and organ failure in hospitalized patients with cirrhosis vary by type of infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3363-3370.	2.8	7
130	Who should treat liver transplant patients? The transplant hepatologist or the gastroenterologist? Part I: The Transplant Hepatologist. <i>Journal of Hepatology</i> , 2006, 44, 655-657.	3.7	6
131	HCV Antiviral Therapy in Liver Transplant Candidates and Recipients With Renal Insufficiency. <i>Transplantation</i> , 2017, 101, 924-932.	1.0	6
132	Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 1328-1336.	2.4	6
133	Current Indications, Contraindications, Delisting Criteria, and Timing for Liver Transplantation. , 2005, , 95-114.		5
134	Steroids in recurrent hepatitis C following liver transplantation: Pitfall or panacea?. <i>Journal of Hepatology</i> , 2007, 47, 741-743.	3.7	5
135	Spontaneous bacterial peritonitis is a risk factor for renal failure requiring dialysis in waitlisted liver transplant candidates. <i>Clinical Transplantation</i> , 2016, 30, 502-507.	1.6	5
136	Patient Perspectives of High-Quality Care on the Liver Transplant Waiting List: A Qualitative Study. <i>Liver Transplantation</i> , 2020, 26, 238-246.	2.4	5
137	Hepatology Highlights. <i>Hepatology</i> , 2021, 74, 1-4.	7.3	5
138	Practices and Perceptions of Living Donor Liver Transplantation, Nondirected Donation, and Liver Paired Exchange: A National Survey. <i>Liver Transplantation</i> , 2022, 28, 774-781.	2.4	5
139	Endoscopic Treatment of Patients with Portal Hypertension. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2001, 11, 1-14.	1.4	4
140	HCV Council "critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. <i>Liver International</i> , 2016, 36, 488-502.	3.9	4
141	Critical Care Management of Gastrointestinal Bleeding and Ascites in Liver Failure. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 566-577.	2.1	4
142	The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol-Associated Hepatitis. <i>Liver Transplantation</i> , 2021, 27, 1382-1391.	2.4	4
143	Predicting outcome of transplantation for cholestatic liver disease: Child-pugh or mayo risk score?. <i>Liver Transplantation</i> , 2000, 6, 759-761.	2.4	2
144	Do Preoperative Inflammatory Markers Impact on Outcome After Liver Transplantation for Hepatocellular Carcinoma?. <i>Annals of Surgery</i> , 2011, 254, 383-384.	4.2	2

#	ARTICLE	IF	CITATIONS
145	Living donor liver transplantation for HCV: Will the true outcomes stand up?. <i>Journal of Hepatology</i> , 2012, 57, 1166-1167.	3.7	2
146	Reply. <i>Hepatology</i> , 2018, 68, 1658-1660.	7.3	2
147	Hepatology Highlights. <i>Hepatology</i> , 2019, 70, 1497-1499.	7.3	2
148	246 "Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients with Alcoholic Hepatitis. <i>Gastroenterology</i> , 2019, 156, S-1186.	1.3	2
149	Evaluation of Alcohol Taxes as a Public Health Opportunity to Reduce Liver Transplant Listings for Alcohol-Related Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 2307-2315.	2.4	2
150	Hepatology Highlights. <i>Hepatology</i> , 2020, 71, 1-3.	7.3	2
151	Post Liver Transplantation Management and Complications. , 2006, , 961-974.		2
152	An Evidence-based Practical Guide to Vaccination for Hepatitis B Virus. <i>Journal of Clinical Gastroenterology</i> , 2022, Publish Ahead of Print, .	2.2	2
153	Current Indications, Contraindications, Delisting Criteria, and Timing For Transplantation. , 2015, , 94-104.		1
154	The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial). <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 263-269.	3.2	1
155	Hepatology Highlights. <i>Hepatology</i> , 2019, 69, 2311-2314.	7.3	1
156	Hepatology Highlights. <i>Hepatology</i> , 2019, 69, 1365-1368.	7.3	1
157	Hepatology Highlights. <i>Hepatology</i> , 2021, 73, 2085-2088.	7.3	1
158	Liver Transplantation: Indications, Preoperative Evaluation and Posttransplantation Management. , 2010, , 1353-1381.		1
159	A Review of Antiviral Use for the Treatment of Chronic Hepatitis B Virus Infection in Pregnant Women. <i>Gastroenterology and Hepatology</i> , 2017, 13, 154-163.	0.1	1
160	Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension. <i>Infectious Diseases and Therapy</i> , 2022, 11, 913-924.	4.0	1
161	Patients with chronic hepatitis C who have normal ALT: A role for interferon-based therapy?. <i>Current Hepatitis Reports</i> , 2003, 2, 11-16.	0.3	0
162	WIN-R revisited: Response to editorial. <i>Hepatology</i> , 2008, 47, 1427-1427.	7.3	0

#	ARTICLE	IF	CITATIONS
163	Thrombocytopenia With Abnormal Liver Function Tests. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 920-923.	4.4	0
164	Hepatitis C viral infection after liver transplantation. <i>Clinical Liver Disease</i> , 2012, 1, 73-76.	2.1	0
165	Reply. <i>Hepatology</i> , 2014, 60, 1448-1448.	7.3	0
166	Reply. <i>Hepatology</i> , 2015, 61, 1439-1439.	7.3	0
167	Reply. <i>Hepatology</i> , 2015, 62, 1328-1329.	7.3	0
168	Reply. <i>Hepatology</i> , 2016, 64, 1824-1825.	7.3	0
169	Hepatology Highlights. <i>Hepatology</i> , 2018, 67, 817-819.	7.3	0
170	Hepatology Highlights. <i>Hepatology</i> , 2018, 67, 1647-1650.	7.3	0
171	Hepatology Highlights. <i>Hepatology</i> , 2018, 67, 1195-1197.	7.3	0
172	Hepatology Highlights. <i>Hepatology</i> , 2018, 67, 461-463.	7.3	0
173	If hepatitis C therapy is so great, why isn't everyone doing it?. <i>American Journal of Transplantation</i> , 2018, 18, 2382-2383.	4.7	0
174	Management of Virologic Failure in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues. <i>Current Hepatology Reports</i> , 2019, 18, 363-369.	0.9	0
175	Hepatology Highlights. <i>Hepatology</i> , 2019, 69, 469-472.	7.3	0
176	Hepatology Highlights. <i>Hepatology</i> , 2019, 69, 1849-1851.	7.3	0
177	Hepatology Highlights. <i>Hepatology</i> , 2019, 69, 927-930.	7.3	0
178	Hepatology Highlights. <i>Hepatology</i> , 2019, 70, 1881-1884.	7.3	0
179	Hepatology Highlights. <i>Hepatology</i> , 2020, 72, 791-793.	7.3	0
180	Hepatology Highlights. <i>Hepatology</i> , 2020, 72, 369-370.	7.3	0

#	ARTICLE	IF	CITATIONS
181	Hepatology Highlights. Hepatology, 2020, 72, 1893-1896.	7.3	0
182	Hepatology Highlights. Hepatology, 2020, 72, 1505-1508.	7.3	0
183	Hepatology Highlights. Hepatology, 2020, 71, 771-773.	7.3	0
184	Hepatology Highlights. Hepatology, 2020, 71, 405-407.	7.3	0
185	Hepatology Highlights. Hepatology, 2020, 71, 1527-1529.	7.3	0
186	Hepatology Highlights. Hepatology, 2020, 71, 1143-1145.	7.3	0
187	Hepatology Highlights. Hepatology, 2021, 73, 1-3.	7.3	0
188	Hepatology Highlights. Hepatology, 2021, 73, 475-478.	7.3	0
189	Reply. Liver Transplantation, 2021, 27, 606-606.	2.4	0
190	Hepatology Highlights. Hepatology, 2021, 73, 1245-1247.	7.3	0
191	Hepatology Highlights. Hepatology, 2021, 74, 539-542.	7.3	0
192	Hepatology Highlights. Hepatology, 2021, 74, 1137-1140.	7.3	0
193	Protecting Patients With Cirrhosis From Coronavirus Disease 2019: Identifying Gaps in Vaccination Rates. Liver Transplantation, 2021, 27, 1535-1537.	2.4	0
194	Hepatology Highlights. Hepatology, 2021, 74, 2329-2332.	7.3	0
195	HCV and Liver Transplantation. Current Hepatology Reports, 0, , 1.	0.9	0
196	The Dilemma of Adult-to-Adult Living Donor Liver Transplantation. , 2009, , 65-89.		0
197	The Current State of Liver Transplantation. Gastroenterology and Hepatology, 2006, 2, 244-246.	0.1	0
198	The Dark Before Dawn. Liver Transplantation, 2022, 28, 533-534.	2.4	0